MCPH1 and ovarian carcinoma: According to a prior study, MCPH1/BRIT1 acts as a negative regulator of the functional variant α+/β+ hTERT in ovarian cancer, while, the α-/β+ hTERT and α-/β- hTERT variants have a positive relationship with MCPH1/BRIT1 supporting its function as a potent inhibitor of telomerase activity (27).